Supplementary Files
Keywords
Child Health
Valsartan
Atrial Natriuretic Factor
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To carry out a literature review of the main pharmacological treatments in the pediatric area, focusing on the class of Neprisilin Inhibitors and angiotensin receptors, in order to expand scientific knowledge on the subject. Bibliographic review: The use of Sacubitril-Valsartan in Heart Failure (HF) with reduced ejection fraction is considered a major advance in the treatment of adults as it reduces hospitalization, general and cardiovascular mortality and sudden death compared to standard therapy. On the other hand, its use in the pediatric class is still restricted due to the existence of few randomized studies on the subject, and the indication so far is individualized and multidisciplinary, shared with family members. Final considerations: It is expected that with the current determination of the Food and Drug Administration (FDA), this medication can be more used in children and adolescents, bringing a reduction in morbidity and mortality and an improvement in the quality of life in this population.
References
ALMOND CSD, et al. Waiting list mortality among children listed for heart transplantation in children in the United States, 2009; 5: 717–727
ARYA A, et al. Angiotensin Receptor and Neprylisin Inhibitor: A new drug in pediatric cardiologist's armamentarium. Ann Pediatr Cardiol, 2020; 13(4): 334-336
AZEKA E, et al. Insuficiência cardíaca congestiva em crianças: do tratamento farmacológico ao transplante cardíaco. Rev Med (São Paulo), 2008; 87(2): 99-104.
BRITO MM. Insuficiência cardíaca na criança. In: Sociedade Brasileira de Pediatria; Leone C, Cabral AS, organizadores. Programa de Atualização em Terapêutica Pediátrica: Ciclo 8. Porto Alegre: Artmed Panamericana; 2021. Sistema de Educação Continuada a Distância, v.2: 11-47
COMITÊ COORDENADOR DA DIRETRIZ DE INSUFICIÊNCIA CARDÍACA. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq Bras Cardiol, 2018; 111(3): 436-539.
DAS BB, et al. Sacubitril/Valsartan: potential treatment for paediatric heart failure. Cardiology in the Young, 2018; 28: 1077-1081
EVERITT MD, et al; Pediatric Cardiomyopathy Registry Investigators. Cardiac Biomarkers in Pediatric Cardiomyopathy: Study Design and Recruitment Results from the Pediatric Cardiomyopathy Registry. Prog Pediatr Cardiol., 2019; 53: 1-10.
HSU DT, PEARSON GD. Heart failure in children: part I: history, etiology, and pathophysiology. Circ Heart Fail, 2009; 2: 63–70.
HUBERS SA e BROWN NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition, 2016; 133(11): 1115-1124
JHUND PS, MCMURRAY JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart, 2016 ;102(17): 1342-1347.
KRUM H. Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): paragon of a study or further investigation paramount? Circulation, 2015; 131(1): 11-2.
MARQUES DA SILVA P, AGUIAR C. Sacubitril/valsartan: um importante avanço no puzzle terapêutico da insuficiência cardíaca. Rev Port Cardiol, 2017; 36: 655-668.
MIYAMOTO SD, et al. Beta-adrenergic adaptation in pediatric idiopathic dilated cardiomyopathy. Eur Heart J, 2014; 35: 33–41.
NAKANO SJ, et al. Pediatric Heart Failure: An Evolving Public Health Concern. J Pediatr, 2020; 218: 217-221.
NAKANO SJ, et al. Cardiac adenylyl cyclase and phosphodiesterase expression profiles vary by age, disease, and chronic phosphodiesterase inhibitor treatment. J Card Fail, 2017; 23 :72–80.
NUNES LC, et al. Associação dos inibidores do cotransportador SGLT2 ao tratamento de insuficiência cardíaca: uma revisão de literatura. REAMed. 2022;10: e 10336. Disponível em: http://dx.doi.org/10.25248/reamed.e10336.2022
PATEL MD, et al. Pediatric and adult dilated cardiomyopathy represent distinct pathological entities. JCI Insight, 2017; 20(2): 94382.
SHADDY R, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trialJAMA, 2007; 298(10): 1171-1179.
SHADDY R, et al. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study). Am Heart J., 2017; 193: 23-34.
U.S NATIONAL LIBRARY OF MEDICINE: CLINICALTRIALS.GOV [INTERNET]. 2016. Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure;
VELAZQUEZ EJ, et al., Rationale and design of the com ParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J., 2018; 198: 145-151.
WILKINSON JD, et al. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. Heart Fail Clin., 2010; 6(4): 401-13.
ROHDE LEP, et al. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq. Bras. Cardiol., 2018; 111(3): 436-539.